Home › All Companies › AKTS

Aktis Oncology, Inc. (AKTS)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-16

Key Insights

  • Aktis Oncology appointed an experienced pharmaceutical executive, Glenn Gormley, MD, PhD, to its board of directors, which could strengthen the company's clinical development and commercialization capabilities.
  • Two existing board members, Helen S. Kim and Oleg Nodelman, have announced their resignations, potentially signaling a change in the company's strategic direction or shareholder representation.
  • The company granted Gormley stock options as part of his board compensation, aligning his interests with those of shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-04-16

Key Insights

  • This Form 4 filing shows that Glenn Gormley, a director of Aktis Oncology, Inc. (AKTS), was granted a stock option to purchase 37,866 shares of the company's common stock at an exercise price of $18.09 per share.
  • The option has a 10-year term and vests over a 3-year period, with 1/3 of the shares vesting on April 15, 2027, and the remaining 2/3 vesting in equal annual installments thereafter.
  • This insider purchase suggests that Gormley is confident in the company's future prospects and aligns his interests with those of shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-03-31

Key Insights

  • Aktis Oncology reported its full-year 2025 financial results, providing an update on the company's business operations.
  • The company did not disclose any specific financial metrics or performance figures in the 8-K filing, limiting the ability to assess its operational and financial health.
  • Without detailed financial information, it is difficult to determine the overall significance of this update for investors.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Annual Report Filed: 2026-03-30

Key Insights

  • Aktis Oncology, Inc. is an emerging growth company developing novel radiopharmaceutical therapies for treating cancer, with two lead product candidates in clinical development targeting Nectin-4 and B7-H3 expressing tumors.
  • The company is facing challenges in securing an adequate supply of the radioactive isotope Actinium-225 (225Ac) needed for its drug candidates, as well as addressing logistical issues around the short half-life of the isotope.
  • Aktis Oncology will need to raise additional funding to complete the ongoing clinical trials for its lead product candidates, which are critical to achieving regulatory approval and commercialization.
  • The company's ability to identify and enroll suitable patients for its clinical trials is a key risk factor that could impact the timing and success of its development programs.
Sentiment: Neutral Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Insider Ansbert Gadicke, a director and 10% owner, significantly increased his beneficial ownership of Aktis Oncology through a series of stock acquisitions and conversions.
  • The reported transactions include the conversion of redeemable convertible preferred stock into common stock, as well as direct purchases of common stock.
  • The increase in Gadicke's ownership position, both directly and through affiliated investment funds, suggests he has a strong conviction in the company's long-term prospects.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • The reporting persons, which include various MPM Capital entities, have converted a significant amount of preferred stock into common stock of Aktis Oncology, Inc. This suggests the investors are bullish on the company's prospects.
  • The reporting persons have also purchased an additional 1,112,777 shares of common stock at $18 per share, further increasing their ownership stake in the company.
  • Insider buying activity is often viewed as a positive signal by investors, as it indicates the reporting persons have confidence in the company's future performance.
Sentiment: Positive Significance: 8/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Insider Todd Foley, who is a 10% owner of Aktis Oncology, Inc. (AKTS), has significantly increased his stake in the company through a series of transactions involving the conversion of preferred stock and open market purchases.
  • The transactions indicate Foley's strong confidence in the company's long-term prospects, as he has acquired over 4.2 million shares, representing a substantial ownership position.
  • The timing of these transactions, just prior to the company's initial public offering, suggests Foley believes the stock is undervalued and has the potential for significant upside as the company goes public.
Sentiment: Positive Significance: 8/10
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Aktis Oncology, Inc. (AKTS) has filed an 8-K disclosing amendments to its certificate of incorporation and bylaws, including the authorization of additional shares of common and preferred stock, the establishment of a classified board, and new provisions related to stockholder proposals and director nominations.
  • The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
  • The amendments to the certificate of incorporation and bylaws indicate potential changes to Aktis Oncology's corporate governance structure and shareholder rights, which investors should closely monitor.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • The reporting person, Lloyd Mitchell Segal, has converted 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock into 19,631 shares of common stock of Aktis Oncology, Inc.
  • The reporting person owns the converted shares indirectly through his ownership of Arvala, Inc., indicating a concentration of insider ownership.
  • The conversion of preferred shares to common shares on a 3.8044-for-1 basis suggests a favorable valuation for the reporting person during the company's initial public offering.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • The reporting person, Helen Susan Kim, is a director and 10% owner of Aktis Oncology, Inc. (AKTS), indicating significant influence and investment in the company.
  • Kim has converted Series A and Series B Redeemable Convertible Preferred Stock into common stock, increasing her beneficial ownership to over 5.6 million shares.
  • The filing suggests insider buying, with Kim purchasing an additional 812,455 shares at $18 per share, further demonstrating confidence in the company's prospects.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • Vida Ventures II, LLC and Vida Ventures II-A, LLC, which collectively own over 10% of Aktis Oncology, Inc. (AKTS), have converted their preferred stock holdings into common stock on a 3.8044-for-1 basis.
  • The reporting persons have also purchased an additional 835,000 shares of AKTS common stock at $18 per share, indicating their continued confidence in the company's prospects.
  • The conversion of preferred stock and additional purchases suggest that the reporting persons believe in the long-term growth potential of AKTS and are willing to increase their stake in the company.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • EcoR1 Capital, LLC, a director and 10% owner of Aktis Oncology, Inc. (AKTS), has acquired a significant amount of common stock and convertible preferred shares through various transactions on January 12, 2026.
  • The reporting persons, EcoR1 Capital, LLC and Oleg Nodelman, are filing the Form 4 jointly but not as a group, and each disclaims beneficial ownership except for their respective pecuniary interests.
  • The conversion of Series A and Series B Redeemable Convertible Preferred Stock into common stock and Class A common stock on a 3.8044-for-1 basis suggests a potential capital restructuring or an initial public offering event for the company.
Sentiment: Positive Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.